2月20日,阿斯利康宣布,与珐博进达成协议,将以约1.6亿美元收购珐博进中国。完成交割后,阿斯利康将获得罗沙司他在中国的所有权利,珐博进保留其在美国及未授权给安斯泰来的市场对罗沙司他的权利。 阿斯利康瞄准了罗沙司他在中国的所有权利,以充实其在中国的现有产品组合。对于正处于困境中的珐博进而言,则可解燃眉之急。该笔交易交割完成后,珐博进将向摩根士丹利管理的投资基金偿还其定期贷款,现金储备也将延长至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.